[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100491181":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":35,"responsibleParty":53,"collaborators":18,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":18,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":18,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group","EXPERIMENTAL","MPA + Atorvastatin",[13],"Drug: Medroxyprogesterone acetate + Atorvastatin",{"label":15,"type":16,"description":17,"interventionNames":18},"Control groups","NO_INTERVENTION","MPA",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Medroxyprogesterone acetate + Atorvastatin","MPA (at a dosage of 250-500 mg\u002Fday,) + Atorvastatin (at a dosage of 20 mg\u002Fday), by mouth,",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"WANG JIANLIU, PhD\u002FMD","CONTACT","+861088324383","wangjianliu1203@163.com",{"name":32,"role":28,"phone":33,"phoneExt":18,"email":34},"HE YIJIAO, PhD","+8618301512017","heyijiao2017@pku.edu.cn",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Wang Jianliu","RECRUITING","Beijing","Beijing Municipality","100044","China","CN",{"type":45,"coordinates":46},"Point",[47,48],116.39723,39.9075,{"lat":48,"lon":47},[51],{"name":52,"role":28,"phone":29,"phoneExt":18,"email":30},"WANG JIANLIU, PHD\u002FMD",{"type":54,"investigatorFullName":37,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Professor, Doctoral supervisor, Chief physician, Vice President","100491181","phase-2-medroxyprogesterone-acetate-plus-atorvastatin-in-young-women-with-early-endometrial-carcinoma-and-atypical-endometrial-hyperplasia-100491181",false,"NCT05675787","Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia","Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma","Inclusion Criteria:\n\n* Have a confirmed pathological diagnosis based upon hysteroscopy: histologically prove AEH or well-differentiated EEC G1 without myometrial invasion: 1. Untreated patients; 2. Patients with persistent lesions after one course (12 weeks) of progesterone therapy; 3. Patients who did not achieve complete remission after 2 courses (24 weeks) of progesterone therapy;\n* No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound\n* Have a desire for remaining reproductive function or uterus\n* Good compliance with adjunctive treatment and follow-up\n\nExclusion Criteria:\n\n* Hypersensitivity or contradiction for using MPA or atorvastatin\n* Pregnancy or potential pregnancy\n* Confirmed diagnosis of any cancer in reproductive system\n* Already diagnosed with hyperlipidemia and using lipid-lowering drugs\n* Acute liver disease or liver tumor (benign or malignant) or renal dysfunction\n* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease\n* With other factors of reproductive dysfunction;\n* Strong request for uterine removal or other conservative treatment\n* Smoker (\\>15 cigarettes a day)\n* Drinker (\\>20 grams a day)","FEMALE","17 Years","45 Years",{"count":67,"type":68},82,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.",[74,75],"Atypical Endometrial Hyperplasia","Endometrial Carcinoma Stage I",[77,74],"Endometrial Carcinoma","2024-07-09",{"date":80,"type":81},"2024-07-11","ACTUAL",{"date":83,"type":81},"2023-01-06",{"date":85,"type":68},"2025-10-31",{"name":5,"class":6},1]